Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis (MS). Subtype 1 of the S1PR is expressed on the surface of lymphocytes and is important in regulating egression from lymph nodes. The S1PR modulators indirectly antagonize the receptor's function leading to sequestration of lymphocytes in the lymph nodes. Fingolimod was the first S1PR modulator to receive regulatory approval for relapsing-remitting MS after 2 phase III trials demonstrated potent efficacy, safety, and tolerability. Fingolimod can cause undesirable effects as a result of its interaction with other S1PR subtypes, which are expressed in diverse tissues, including cardiac myocytes. As such, agents that more selectively target subtype 1 of the S1PR are of interest and are at various stages of development. These include ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303. Data from phase II trials and early results from phase III studies have been promising and will be presented in this review. Of special interest are results from the EXPAND study of siponimod, which suggest a potential role for S1PR modulators in secondary progressive MS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722770 | PMC |
| http://dx.doi.org/10.1007/s13311-017-0565-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Gastroenterol Hepatol
January 2025
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency in 2024, constituting a new therapeutic option for the treatment of moderately to severely active ulcerative colitis in patients 16 years of age and older in the European Union. Its efficacy and tolerability have been demonstrated in several clinical trials both as induction and maintenance treatment, as well as in long-term extension studies.
View Article and Find Full Text PDF[Treatment of severe flares in Crohn's disease and ulcerative colitis].
Inn Med (Heidelb)
January 2025
Abteilung für interventionelle gastroenterologische Endoskopie, Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Deutschland.
Background: In chronic inflammatory bowel diseases (IBD), severe flares are characterized by intense inflammatory activity and a high disease burden for patients. Treatment addresses both short-term goals (e.g.
View Article and Find Full Text PDFTargeting mucosal healing in Crohn's disease: efficacy of novel pathways and therapeutic targets.
Expert Opin Ther Targets
November 2024
Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy.
Introduction: Crohn's disease (CD) is a chronic inflammatory bowel disease affecting the entire gastrointestinal tract with a progressive and relapsing course. Achieving mucosal healing has emerged as a critical therapeutic goal, as it is associated with sustained clinical remission, reduced hospitalizations, and fewer surgery rates. Therefore, targeting mucosal healing is essential for long-term control in CD.
View Article and Find Full Text PDFUnique pharmacological properties of etrasimod among S1P receptor modulators.
FEBS Open Bio
January 2025
Arena Pharmaceuticals, San Diego, CA, USA.
Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune-mediated inflammatory diseases. Interaction between S1P and its five receptor subtypes (S1P-S1P) plays a role in several physiologic systems, including the cardiovascular and immune systems. Since differences in S1PR binding and downstream intracellular signaling could contribute to distinct profiles of drug efficacy and safety, we directly compared the S1P selectivity profile of etrasimod to three marketed S1PR modulators: fingolimod, ozanimod, and siponimod.
View Article and Find Full Text PDFProgressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.
Mult Scler Relat Disord
December 2024
Division of Pharmacovigilance I, Office of Surveillance and Epidemiology (DC, TK, VC, AB), Center for Drug Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Background: Risk factors for progressive multifocal leukoencephalopathy (PML) associated with sphingosine-1-phosphate receptor (S1PR) modulators are not as well-characterized as for natalizumab. We characterized S1PR modulator-associated PML cases and risk factors for PML using spontaneous adverse event reports.
Methods: We reviewed case reports from the FDA Adverse Event Reporting System database and the medical literature.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!